Akero Therapeutics

INDICAL Inc is a global biotech company with over two decades of experience in developing and commercializing innovative diagnostic solutions for veterinary applications. They offer a wide range of products, including sample preparation instruments, assays, and reagents for various animal species, such as ruminants, swine, avian poultry, equine, and companion animals. INDICAL is committed to improving diagnostics for better animal and human health. With a global network covering 169 countries and 75 commercial partners, INDICAL is known for its expertise in providing reliable results and certainty for the future. They prioritize customer satisfaction and work closely with customers to achieve technology and workflow excellence. INDICAL also actively participates in conferences and events worldwide, sharing their knowledge and supporting veterinary practice, research, and science.Generated from the website

Zenith Epigenetics Corp is a clinical-stage biotechnology company based in San Francisco, specializing in the development of bromodomain and extra-terminal inhibitors (BETi) aimed at treating various cancers and other critical disorders. The company prioritizes translating epigenetic biology into effective targeted therapies, with a focus on innovative clinical development and translational medicine. With an experienced research team, Zenith Epigenetics has established a robust epigenetic platform to create potent and selective BET inhibitors. Their lead compound, ZEN-3694, is currently under Phase 2 clinical development for prostate and breast cancer, the latter in collaboration with Pfizer, highlighting their commitment to addressing significant unmet medical needs in oncology. Generated from the website

Resverlogix Inc is a late-stage clinical biotechnology company based in San Francisco, CA. Founded in 2001, the company focuses on developing safe and effective therapeutics for patients suffering from chronic illnesses. With a strong emphasis on epigenetics, Resverlogix is a global leader in the development of a new class of drugs designed to regulate disease-associated epigenetics, particularly in cardiovascular diseases. Resverlogix's flagship drug, apabetalone, has received Breakthrough Therapy designation from the US FDA, positioning the company at the forefront of modern medicine. Through their science programs and global Phase 3 clinical trial, BETonMACE, Resverlogix aims to provide innovative solutions to key stakeholders, including payer groups, and improve the lives of patients with high unmet medical needs.Generated from the website